Nutriband is engaged in the development of a portfolio of transdermal pharmaceutical products. Co.'s key product is its abuse deterrent fentanyl transdermal system which it is developing to provide clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy combined with properties designed to help combat the opioid crisis by deterring the abuse and misuse of fentanyl patches. Co. is developing a portfolio of transdermal pharmaceutical products to deliver commercially available drugs or biologics that are delivered by injection but with the potential to improve compliance and therapeutic outcomes. The NTRB average annual return since 2021 is shown above.
The Average Annual Return on the NTRB average annual return since 2021 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether NTRB average annual return since 2021 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the NTRB average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|